Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

COPENHAGEN, Denmark, April 9, 2025– Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors' proposal to transfer the Company's result to 2025 was also adopted.The Remuneration Report for 2024 was not approved. It is noted that this was an indicative vote, and that the decision will not entail consequences on the reported remuneration. The Board of Directors will discuss the...

Hellerup, 09/04/2025 (informazione.news - comunicati stampa - salute e benessere)

COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results:

The full proposals are available on the notice for the Annual General Meeting.

Minutes and voting results from the Annual General Meeting will be published on the Company's website within two weeks.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Contact investors:
Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: + 45 53 88 06 03

Company Announcement no. 13 / 2025

Attachment